Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Cisplatin was the first metal-based therapeutic agent approved for the treatment of human cancers, but its clinical activity is greatly limited by tumor drug resistance. This work utilized the parent complex [Ru(phen)(2)(PIP)](2+) (1) to develop three Ru(II) complexes (2–4) with different positional...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Leli, Chen, Yu, Liu, Jiangping, Huang, Huaiyi, Guan, Ruilin, Ji, Liangnian, Chao, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725915/
https://www.ncbi.nlm.nih.gov/pubmed/26763798
http://dx.doi.org/10.1038/srep19449

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725915/
https://www.ncbi.nlm.nih.gov/pubmed/26763798
http://dx.doi.org/10.1038/srep19449

Ejemplares similares